Daclatasvir 1009119-65-6

Daclatasvir (Daklinza) has obtained "priority review" status, combined with sorafenib
for the treatment of genotype III adult patients with chronic hepatitis C. Daklinza has been the first drug
that has been proved of being effective in the treatment of genotype III hepatitis C virus infection
without the co-administration with interferon or ribavirin.
Interferon and ribavirin are two drugs approved by FDA for the treatment of hepatitis C virus infection.
Hepatitis C is a viral disease that can cause inflammation of the liver,
resulting in decreased liver function or liver failure. Most patients infected
with hepatitis C have no symptoms until liver damage becomes apparent, which may take several years.

Globally, genotype III hepatitis C is the second most common genotype of hepatitis C
after genotype 1 hepatitis C and is considered to be one of the most refractory genotype diseases.
Daklinza is a pan-genotype NS5A replication complex inhibitor,
with efficacy of inhibition of RNA replication and viral assembly, dual antiviral effect.